CA
ECYT

Cliff Asness’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Cliff Asness’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-52,204
Closed -$927K – 2351
2018
Q3 		$927K Sell
52,204
-20,986
-29% -$360K ﹤0.01% 1732
2018
Q2 		$1.01M Buy
+73,190
New +$869K ﹤0.01% 1720
2015
Q4 		– Sell
-24,453
Closed -$112K – 2350
2015
Q3 		$112K Sell
24,453
-82,406
-77% -$431K ﹤0.01% 2119
2015
Q2 		$555K Sell
106,859
-87,141
-45% -$523K ﹤0.01% 1729
2015
Q1 		$1.22M Sell
194,000
-18,100
-9% -$104K ﹤0.01% 1330
2014
Q4 		$1.33M Buy
212,100
+157,200
+286% +$958K ﹤0.01% 1515
2014
Q3 		$334K Buy
54,900
+2,700
+5% +$18.4K ﹤0.01% 2126
2014
Q2 		$344K Sell
52,200
-421,880
-89% -$4.75M ﹤0.01% 2148
2014
Q1 		$11.3M Buy
474,080
+371,000
+360% +$5.38M 0.03% 550
2013
Q4 		$1.1M Sell
103,080
-137,364
-57% -$1.52M ﹤0.01% 1682
2013
Q3 		$3.21M Sell
240,444
-51,136
-18% -$808K 0.01% 1017
2013
Q2 		$3.83M Buy
+291,580
New +$3.93M 0.01% 978

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Cliff Asness's ECYT Position: Q4 2018 in Review

Cliff Asness sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 52,204 shares — an estimated $927K sold.

Cliff Asness first reported a position in ECYT in Q2 2013 and held it in 12 quarters. The position peaked at $11.3M in Q1 2014. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Cliff Asness reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Cliff Asness sold 52,204 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $927K.
  • Cliff Asness first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
  • Cliff Asness's Endocyte, Inc. Common Stock position peaked at $11.3M in Q1 2014.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on AQR Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.